Cell & Gene Therapy Optimization, a Framework: Assessing Efficacy and Safety with Dynamic Biomarkers

Cell and gene therapies hold enormous potential as new treatment modalities for traditionally difficult-to-treat diseases. There are still challenges, however, stemming from heterogeneity in target engagement and drug response across patients, as well as adverse events. This presentation explores use of discovery mass spectrometry to identify dynamic biomarkers of response and adverse events throughout the course of cell and gene therapy.
Presented by Dr. Mo Jain, Founder and CEO of Sapient
Hosted by AAPS

[@JohnnyThomas-py3jv]

don't normally comment on videos, but I'm glad you been posting more